Related references
Note: Only part of the references are listed.Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
Donna E. Reece et al.
BLOOD (2011)
Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Giada Bianchi et al.
BLOOD (2009)
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
Donna E. Reece et al.
BLOOD (2009)
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
Ashutosh D. Wechalekar et al.
HAEMATOLOGICA (2008)
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
Efstathios Kastritis et al.
HAEMATOLOGICA (2007)
Molecular mechanisms of amyloidosis
G Merlini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
